ClinicalTrials.gg
CompletedNCT06402123PRIZMUpdated Oct 23, 2026

A Phase 2b Study of Zagociguat in Patients With MELAS

A Phase 2 interventional study of zagociguat 15mg and zagociguat 30mg in Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome), sponsored by Tisento Therapeutics. Completed at 20 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment

Updated Oct 6, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Acidosis, Lactic with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Acidosis, Lactic · United States.

Enrollment
2nd of 14
43 · median 29
Started
2024
the only one that year
Phase 2
6 of 19
none open now
Registered
17th of 19
by date
Lead sponsor
2 of 19
Tisento Therapeutics

Among the 19 studies in Acidosis, Lactic with a site in United States, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 2, and was the 17th registered.

Acidosis, Lactic

48 studies on the registry are indexed under Acidosis, Lactic; 5 are open to participants now.

Browse Acidosis, Lactic studies →

Open to participants now

2 of the 19 studies in Acidosis, Lactic with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Acidosis, Lactic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acidosis, Lactic with a site in United States, or all of them as a file.
02

Study summary

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.

Read the detailed description

The goal of this clinical trial is to learn about the effectiveness of zagociguat in patients with MELAS. The main questions it aims to answer are:

  • Does zagociguat improve fatigue in patients with MELAS?
  • Does zagociguat improve cognitive performance in patients with MELAS?
  • What is the safety and tolerability profile of zagociguat?

The PRIZM study is evaluating 2 dose levels of zagociguat in a crossover design consisting of two 12-week treatment periods separated by a 4-week washout. Patients will be screened and if eligible, randomly assigned either to receive placebo in period 1 followed by active drug in period 2 OR to receive active drug in period 1 followed by placebo in period 2. Study medication is a once daily oral tablet and will be provided at the clinic and/or shipped to the participant's home. Clinic visits will occur at screening and Week 1 and Week 12 of each treatment period. Visits at Week 4 and Week 8 of both crossover periods will either be in clinic or optionally at the participant's home. Study assessments will be conducted weekly on a phone app and a separate tablet and additional assessments will be conducted during visits. Patients who complete the study will be eligible for an open label extension study.

03

Conditions studied

  • Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Keywords

  • MELAS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed consent form.
  2. 18 to 75 years of age.
  3. Diagnosed with MELAS based on the presence of each of the following criteria:

    1. A documented pathogenic variant in a mitochondrial DNA (mtDNA) gene.
    2. History of one or more stroke-like episodes (SLEs) with magnetic resonance imaging (MRI) findings consistent with stroke-like lesions.
  4. Scores below normal average on the iDSST and GMLT.
  5. Reports fatigue due to MELAS.
  6. Can complete at least 1 sit-to-stand in the 30-second test interval.
  7. Completes all at-home weekly activities independently during the Screening Period (caregiver may help set up device/app, log-in, etc.).
  8. Other criteria per the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure (BP) 90 mmHg or diastolic BP 60 mmHg.
  2. Orthostatic hypotension when measured after standing from a semi-recumbent/supine position.
  3. Active cancer significant enough to confound the results of this study.
  4. Severe gastrointestinal dysmotility that may impact participation.
  5. Recent history (within last 6 months) of dysfunction, hemophilia, von Willebrand disease, coagulation disorder, other bleeding diathesis condition(s), or significant, nontraumatic bleeding episodes.
  6. History of spontaneous fracture(s) that in the investigator's opinion represents a safety risk for trial participation.
  7. Current use of prohibited medication (reviewed by investigator).
  8. Any medical or other condition that the investigator thinks would preclude study participation.
  9. Other exclusion criteria per protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Placebo then Zagociguat 15mg

    Participants first receive placebo once a day for 12 weeks. Then after a 4 week washout, they receive zagociguat 15 mg once a day for 12 weeks.

    Drug: zagociguat 15mg · Drug: Placebo

  • Experimental
    Zagociguat 15mg then Placebo

    Participants first receive zagociguat 15 mg once a day for 12 weeks. Then after a 4-week washout, they receive placebo once a day for 12 weeks.

    Drug: zagociguat 15mg · Drug: Placebo

  • Experimental
    Placebo then Zagociguat 30mg

    Participants first receive placebo once a day for 12 weeks. Then after a 4-week washout, they receive zagociguat 30 mg once a day for 12 weeks.

    Drug: zagociguat 30mg · Drug: Placebo

  • Experimental
    Zagociguat 30mg then Placebo

    Participants first receive zagociguat 30 mg once a day for 12 weeks. Then after a 4-week washout, they receive placebo once a day for 12 weeks.

    Drug: zagociguat 30mg · Drug: Placebo

Interventions

  • Once-daily oral tablets

    Also known as: IW-6463, CY6463

  • Once-daily oral tablets

    Also known as: IW-6463, CY6463

  • DrugPlacebo

    Once-daily oral tablets

06

What researchers measure

Primary outcomes

  1. • PROMIS Fatigue MELAS Short Form scores• Groton Maze Learning Test scores • International Digit Symbol Substitution Test scores

    These measures are a patient reported questionnaire on MELAS-specific fatigue and 2 cognitive performance tests. These 3 outcome measures will be combined using a global statistical test.

    Time frame: Weeks 9 through 12 of each treatment period

  2. Incidence of Treatment-emergent Adverse Events (TEAEs)

    TEAEs are any untoward event that may or may not be related to study medication.

    Time frame: Weeks 1 through washout for treatment period 1 and Weeks 1 through follow-up for treatment period 2

Secondary outcomes

  1. Number of repetitions completed during the 30-second sit-to-stand test

    Leg strength and exercise intolerance

    Time frame: Week 12

  2. PROMIS Cognitive Function MELAS Short Form (PCFM-SF) score

    Patient-reported questionnaire on MELAS-specific cognitive function

    Time frame: Week 12

  3. Plasma concentrations of GDF-15

    Measure of disease pathophysiology

    Time frame: Week 12

  4. Memory composite scores (One Card Learning and One Back Tests) for Week 9 through 12

    Test of memory

    Time frame: Week 9 through 12

07

Study locations

20 sites
  • UC San Diego - Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Columbia University Irving Medical Center
    New York, New York 10027, United States
  • Mount Sinai - Ichan School of Medicine
    New York, New York 10029, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • Neuroscience Research Australia
    Sydney, New South Wales NSW 2031, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3052, Australia
  • Shared Health/University of Manitoba
    Winnipeg, Manitoba R3A1R9, Canada
  • McMaster University Medical Center
    Hamilton, Ontario L8N 3Z5, Canada
  • University Hospital Bonn
    Bonn, 53127, Germany
  • Ludwig-Maximilians-University of Munich
    Munich, 80336, Germany
  • Neurologic Institute Carlo Besta of Milan
    Milan, 20133, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • UCL Queen Square Institute of Neurology
    London, London WC1N 3BG, United Kingdom
  • Newcastle University
    Newcastle upon Tyne, NE14LP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jun 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 7, 2024
StartActual
Sep 10, 2024
Primary completionActual
Jun 29, 2026
CompletionActual
Jun 29, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • UCL Queen Square Institute of Neurology · London, United Kingdom
Show 1 removed
  • UCL Queen Square Institute of Neurology · London, United Kingdom
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • UCL Queen Square Institute of Neurology · London, United Kingdom
    Show 1 removed
    • UCL Queen Square Institute of Neurology · London, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06402123
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
May 7, 2024
Start date
Sep 10, 2024
Primary completion
Jun 29, 2026
Completion
Jun 29, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion